2 results
Approved WMORecruiting
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
Approved WMORecruiting
Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and dexamethasone (DVd) in terms of progression-free survival (PFS) in subjects with RRMMSecondary objectives:• In…